Shorter (≤ 6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: A meta-analysis of randomized clinical trials

Anil Pandit, Smith Giri, Fayaz Ahmad Hakim, F. David Fortuin

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objective: Optimal duration of dual antiplatelet therapy (DAPT), defined as use of both aspirin and a P2Y12 receptor inhibitor, after implantation of drug eluting stents (DES) is still subject of ongoing debate. We systematically review efficacy and safety of ≤6 months versus ≥12 months DAPT after implantation of DES. Methods: PubMed, Scopus, Cochrane, and clinicaltrials.gov databases were searched for studies published until 30th November 2013. The studies were limited to randomized clinical trials. Independent observers abstracted the data on outcomes, characteristics, and qualities of studies included. Random effect model was employed for meta-analysis. Heterogeneity of studies included was analyzed using I2 statistics. Results: In four randomized clinical trials published involving 8,163 patients with DES, 4,081 patients were randomized to shorter and 4,082 patients to longer duration DAPT. The P2Y12 receptor inhibitor used in all four studies was clopidogrel. Longer duration of DAPT did not reduce risk of all cause mortality (pooled OR 0.89, 95% CI 0.67-1.17, P = 0.4, I2 = 0%), myocardial infarction (pooled OR 1.16, 95% CI 0.85-1.57, P = 0.35, I2 = 0%) cardiac death (pooled OR 0.88, 95% CI 0.61-1.25, P = 0.47, I2 = 0%), stent thrombosis (pooled OR 1.29, 95% CI 0.76-2.21, P = 0.35, I2 = 0%) or cerebrovascular accidents (pooled OR 0.73, 95% CI 0.41-1.27, P = 0.26, I2 = 0%). Longer duration of DAPT was associated with increased risk of TIMI major bleeding (pooled OR 0.51, 95% CI 0.29-0.89, P = 0.02, I2 = 0%). Conclusion: There was no difference in efficacy outcomes between ≤6 months of DAPT and ≥12 months of DAPT in patients with coronary artery disease and DES implantation. Moreover, longer duration of DAPT is associated with increased risk of bleeding complications.

Original languageEnglish (US)
Pages (from-to)34-40
Number of pages7
JournalCatheterization and Cardiovascular Interventions
Volume85
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Drug-Eluting Stents
Meta-Analysis
Randomized Controlled Trials
clopidogrel
Therapeutics
Hemorrhage
PubMed
Aspirin
Stents
Coronary Artery Disease
Thrombosis
Stroke
Myocardial Infarction
Databases
Safety
Mortality

Keywords

  • Antiplatelet therapy
  • Coronary artery disease
  • Drug eluting stent

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Shorter (≤ 6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents : A meta-analysis of randomized clinical trials. / Pandit, Anil; Giri, Smith; Hakim, Fayaz Ahmad; Fortuin, F. David.

In: Catheterization and Cardiovascular Interventions, Vol. 85, No. 1, 01.01.2015, p. 34-40.

Research output: Contribution to journalArticle

@article{7e46f609f06e40fb8e37531d1cce279e,
title = "Shorter (≤ 6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: A meta-analysis of randomized clinical trials",
abstract = "Objective: Optimal duration of dual antiplatelet therapy (DAPT), defined as use of both aspirin and a P2Y12 receptor inhibitor, after implantation of drug eluting stents (DES) is still subject of ongoing debate. We systematically review efficacy and safety of ≤6 months versus ≥12 months DAPT after implantation of DES. Methods: PubMed, Scopus, Cochrane, and clinicaltrials.gov databases were searched for studies published until 30th November 2013. The studies were limited to randomized clinical trials. Independent observers abstracted the data on outcomes, characteristics, and qualities of studies included. Random effect model was employed for meta-analysis. Heterogeneity of studies included was analyzed using I2 statistics. Results: In four randomized clinical trials published involving 8,163 patients with DES, 4,081 patients were randomized to shorter and 4,082 patients to longer duration DAPT. The P2Y12 receptor inhibitor used in all four studies was clopidogrel. Longer duration of DAPT did not reduce risk of all cause mortality (pooled OR 0.89, 95{\%} CI 0.67-1.17, P = 0.4, I2 = 0{\%}), myocardial infarction (pooled OR 1.16, 95{\%} CI 0.85-1.57, P = 0.35, I2 = 0{\%}) cardiac death (pooled OR 0.88, 95{\%} CI 0.61-1.25, P = 0.47, I2 = 0{\%}), stent thrombosis (pooled OR 1.29, 95{\%} CI 0.76-2.21, P = 0.35, I2 = 0{\%}) or cerebrovascular accidents (pooled OR 0.73, 95{\%} CI 0.41-1.27, P = 0.26, I2 = 0{\%}). Longer duration of DAPT was associated with increased risk of TIMI major bleeding (pooled OR 0.51, 95{\%} CI 0.29-0.89, P = 0.02, I2 = 0{\%}). Conclusion: There was no difference in efficacy outcomes between ≤6 months of DAPT and ≥12 months of DAPT in patients with coronary artery disease and DES implantation. Moreover, longer duration of DAPT is associated with increased risk of bleeding complications.",
keywords = "Antiplatelet therapy, Coronary artery disease, Drug eluting stent",
author = "Anil Pandit and Smith Giri and Hakim, {Fayaz Ahmad} and Fortuin, {F. David}",
year = "2015",
month = "1",
day = "1",
doi = "10.1002/ccd.25520",
language = "English (US)",
volume = "85",
pages = "34--40",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Shorter (≤ 6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents

T2 - A meta-analysis of randomized clinical trials

AU - Pandit, Anil

AU - Giri, Smith

AU - Hakim, Fayaz Ahmad

AU - Fortuin, F. David

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objective: Optimal duration of dual antiplatelet therapy (DAPT), defined as use of both aspirin and a P2Y12 receptor inhibitor, after implantation of drug eluting stents (DES) is still subject of ongoing debate. We systematically review efficacy and safety of ≤6 months versus ≥12 months DAPT after implantation of DES. Methods: PubMed, Scopus, Cochrane, and clinicaltrials.gov databases were searched for studies published until 30th November 2013. The studies were limited to randomized clinical trials. Independent observers abstracted the data on outcomes, characteristics, and qualities of studies included. Random effect model was employed for meta-analysis. Heterogeneity of studies included was analyzed using I2 statistics. Results: In four randomized clinical trials published involving 8,163 patients with DES, 4,081 patients were randomized to shorter and 4,082 patients to longer duration DAPT. The P2Y12 receptor inhibitor used in all four studies was clopidogrel. Longer duration of DAPT did not reduce risk of all cause mortality (pooled OR 0.89, 95% CI 0.67-1.17, P = 0.4, I2 = 0%), myocardial infarction (pooled OR 1.16, 95% CI 0.85-1.57, P = 0.35, I2 = 0%) cardiac death (pooled OR 0.88, 95% CI 0.61-1.25, P = 0.47, I2 = 0%), stent thrombosis (pooled OR 1.29, 95% CI 0.76-2.21, P = 0.35, I2 = 0%) or cerebrovascular accidents (pooled OR 0.73, 95% CI 0.41-1.27, P = 0.26, I2 = 0%). Longer duration of DAPT was associated with increased risk of TIMI major bleeding (pooled OR 0.51, 95% CI 0.29-0.89, P = 0.02, I2 = 0%). Conclusion: There was no difference in efficacy outcomes between ≤6 months of DAPT and ≥12 months of DAPT in patients with coronary artery disease and DES implantation. Moreover, longer duration of DAPT is associated with increased risk of bleeding complications.

AB - Objective: Optimal duration of dual antiplatelet therapy (DAPT), defined as use of both aspirin and a P2Y12 receptor inhibitor, after implantation of drug eluting stents (DES) is still subject of ongoing debate. We systematically review efficacy and safety of ≤6 months versus ≥12 months DAPT after implantation of DES. Methods: PubMed, Scopus, Cochrane, and clinicaltrials.gov databases were searched for studies published until 30th November 2013. The studies were limited to randomized clinical trials. Independent observers abstracted the data on outcomes, characteristics, and qualities of studies included. Random effect model was employed for meta-analysis. Heterogeneity of studies included was analyzed using I2 statistics. Results: In four randomized clinical trials published involving 8,163 patients with DES, 4,081 patients were randomized to shorter and 4,082 patients to longer duration DAPT. The P2Y12 receptor inhibitor used in all four studies was clopidogrel. Longer duration of DAPT did not reduce risk of all cause mortality (pooled OR 0.89, 95% CI 0.67-1.17, P = 0.4, I2 = 0%), myocardial infarction (pooled OR 1.16, 95% CI 0.85-1.57, P = 0.35, I2 = 0%) cardiac death (pooled OR 0.88, 95% CI 0.61-1.25, P = 0.47, I2 = 0%), stent thrombosis (pooled OR 1.29, 95% CI 0.76-2.21, P = 0.35, I2 = 0%) or cerebrovascular accidents (pooled OR 0.73, 95% CI 0.41-1.27, P = 0.26, I2 = 0%). Longer duration of DAPT was associated with increased risk of TIMI major bleeding (pooled OR 0.51, 95% CI 0.29-0.89, P = 0.02, I2 = 0%). Conclusion: There was no difference in efficacy outcomes between ≤6 months of DAPT and ≥12 months of DAPT in patients with coronary artery disease and DES implantation. Moreover, longer duration of DAPT is associated with increased risk of bleeding complications.

KW - Antiplatelet therapy

KW - Coronary artery disease

KW - Drug eluting stent

UR - http://www.scopus.com/inward/record.url?scp=84923205768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923205768&partnerID=8YFLogxK

U2 - 10.1002/ccd.25520

DO - 10.1002/ccd.25520

M3 - Article

C2 - 24753084

AN - SCOPUS:84923205768

VL - 85

SP - 34

EP - 40

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 1

ER -